Activity of antibiotics against Burkholderia cepacia complex in artificial sputum medium.

IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Journal of Antimicrobial Chemotherapy Pub Date : 2024-11-04 DOI:10.1093/jac/dkae299
Anusha Shukla, Shade Rodriguez, Thea Brennan-Krohn
{"title":"Activity of antibiotics against Burkholderia cepacia complex in artificial sputum medium.","authors":"Anusha Shukla, Shade Rodriguez, Thea Brennan-Krohn","doi":"10.1093/jac/dkae299","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Burkholderia cepacia complex (Bcc) is a collection of intrinsically drug-resistant Gram-negative bacteria that cause life-threatening disease in people with cystic fibrosis (CF). Standard antimicrobial susceptibility testing methods have poor predictive value for clinical outcomes in Bcc infections, probably due in part to differences between in vitro testing conditions and the environment in which Bcc grow in the lungs of people with CF.</p><p><strong>Objectives: </strong>To compare the activity of commonly used antibiotics under standard in vitro testing conditions with activity in conditions mimicking those found in vivo.</p><p><strong>Methods: </strong>Two Bcc strains were grown alone and with six different antibiotics (minocycline, ceftazidime, meropenem, tobramycin, levofloxacin, trimethoprim-sulfamethoxazole) in two different media: standard cation-adjusted Mueller-Hinton broth and an artificial sputum medium designed to simulate the environment in the lungs of people with CF through addition of components including mucin, free DNA and amino acids. Two different starting conditions were used for time-kill assays: a standard ∼5 × 106 cfu/mL inoculum, and a high-density inoculum in which bacteria were grown for 72 hours before addition of antibiotics. Growth detection was performed by colony enumeration and by detection of resazurin reduction.</p><p><strong>Results: </strong>There were major discrepancies between standard susceptibility results and activity in our models. Some antibiotics, including ceftazidime, showed minimal activity in all time-kill assays despite low minimal inhibitory concentrations, while others, notably tobramycin, were more active in high-density growth conditions than in standard time-kill assays.</p><p><strong>Conclusions: </strong>This work underscores the urgent need to develop more clinically relevant susceptibility testing approaches for Bcc.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"2867-2876"},"PeriodicalIF":3.9000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531831/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antimicrobial Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jac/dkae299","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Burkholderia cepacia complex (Bcc) is a collection of intrinsically drug-resistant Gram-negative bacteria that cause life-threatening disease in people with cystic fibrosis (CF). Standard antimicrobial susceptibility testing methods have poor predictive value for clinical outcomes in Bcc infections, probably due in part to differences between in vitro testing conditions and the environment in which Bcc grow in the lungs of people with CF.

Objectives: To compare the activity of commonly used antibiotics under standard in vitro testing conditions with activity in conditions mimicking those found in vivo.

Methods: Two Bcc strains were grown alone and with six different antibiotics (minocycline, ceftazidime, meropenem, tobramycin, levofloxacin, trimethoprim-sulfamethoxazole) in two different media: standard cation-adjusted Mueller-Hinton broth and an artificial sputum medium designed to simulate the environment in the lungs of people with CF through addition of components including mucin, free DNA and amino acids. Two different starting conditions were used for time-kill assays: a standard ∼5 × 106 cfu/mL inoculum, and a high-density inoculum in which bacteria were grown for 72 hours before addition of antibiotics. Growth detection was performed by colony enumeration and by detection of resazurin reduction.

Results: There were major discrepancies between standard susceptibility results and activity in our models. Some antibiotics, including ceftazidime, showed minimal activity in all time-kill assays despite low minimal inhibitory concentrations, while others, notably tobramycin, were more active in high-density growth conditions than in standard time-kill assays.

Conclusions: This work underscores the urgent need to develop more clinically relevant susceptibility testing approaches for Bcc.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人工痰培养基中抗生素对伯克霍尔德氏菌复合体的活性。
背景:伯克霍尔德氏菌复合菌(Bcc)是一组具有内在耐药性的革兰氏阴性菌,可导致囊性纤维化(CF)患者出现危及生命的疾病。标准的抗菌药敏感性测试方法对 Bcc 感染的临床结果预测价值较低,部分原因可能是体外测试条件与 Bcc 在 CF 患者肺部的生长环境存在差异:目的:比较常用抗生素在标准体外试验条件下的活性和在模拟体内试验条件下的活性:方法: 在两种不同的培养基(标准阳离子调整型穆勒-欣顿肉汤和人工痰培养基)中分别培养两株Bcc菌株和六种不同的抗生素(米诺环素、头孢他啶、美罗培南、妥布霉素、左氧氟沙星、三甲氧苄氨嘧啶-磺胺甲噁唑),这两种培养基分别是标准阳离子调整型穆勒-欣顿肉汤和人工痰培养基,前者旨在通过添加粘蛋白、游离DNA和氨基酸等成分来模拟CF患者的肺部环境。时间杀伤试验使用了两种不同的起始条件:一种是标准的 ∼5 × 106 cfu/mL 接种物,另一种是高密度接种物,细菌在其中生长 72 小时后再添加抗生素。生长检测通过菌落计数和检测利马唑啉还原进行:结果:在我们的模型中,标准药敏结果与活性之间存在很大差异。包括头孢他啶在内的一些抗生素尽管最小抑菌浓度较低,但在所有时间致死试验中都表现出极小的活性,而其他抗生素,尤其是妥布霉素,在高密度生长条件下比在标准时间致死试验中更具活性:结论:这项研究表明,亟需开发更多与临床相关的 Bcc 药敏试验方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.20
自引率
5.80%
发文量
423
审稿时长
2-4 weeks
期刊介绍: The Journal publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, and articles in veterinary medicine likely to have an impact on global health.
期刊最新文献
Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion. Efficacy and tolerability of high-dose cefalexin 45 mg/kg/dose (maximum 1.5 g) three times daily in children with bone and joint infections. Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting. Comment on: Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia. Insights into interspecies protein binding variability using clindamycin as an example.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1